Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease?

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Li, Xinyi ^a   Buxbaum, Joel N ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Aggregation; Alzheimer's disease (AD); Amyloidosis; Beta amyloid (A ); Beta amyloid precursor protein (A PP, APP); Protein homeostasis; Transthyretin (TTR)

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN A1; CYSTATIN C; GELSOLIN; MESSENGER RNA; NEUROSERPIN; PREALBUMIN; RECOMBINANT PROTEIN; RECOMBINANT TRANSTHYRETIN; RETINOIC ACID; UNCLASSIFIED DRUG; APP PROTEIN, HUMAN; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; AMYLOIDOSIS; BRAIN NERVE CELL; CAENORHABDITIS ELEGANS; CEREBROSPINAL FLUID LEVEL; CYTOTOXICITY; DRUG EFFECT; GENE MUTATION; GLIOSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MOLECULAR INTERACTION; MUSCLE CELL; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; TRANSGENIC MOUSE; WILD TYPE; WORM; AGING; ANIMAL; BRAIN; CHEMISTRY; DISEASE MODEL; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION;

CAENORHABDITIS ELEGANS; MUS MUSCULUS;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; PREALBUMIN; PROTEIN MULTIMERIZATION;

EID: 81555232259     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-79     Document Type: Review

References (239)

1. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P, Amyloid 2010 17 101 104
2. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Goldschmidt L, Teng PK, Riek R, Eisenberg D, Proc Natl Acad Sci USA 2010 107 3487 3492
3. Life on the edge: a link between gene expression levels and aggregation rates of human proteins. Tartaglia GG, Pechmann S, Dobson CM, Vendruscolo M, Trends Biochem Sci 2007 32 204 206 (Pubitemid 46694330)
4. The biological and chemical basis for tissue-selective amyloid disease. Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller SR, Sawkar AR, Balch WE, Kelly JW, Cell 2005 121 73 85
5. Relationship of amyloid to aging. Review of the literature and systematic study of 83 patients derived rom a general hospital population. Wright JR, Calkins E, Breen WJ, Stolte G, Schultz RT, Medicine 1969 48 39 60
6. Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis. Bergstrom J, Murphy C, Eulitz M, Weiss DT, Westermark GT, Solomon A, Westermark P, Biochem Biophys Res Commun 2001 285 903 908 (Pubitemid 32918021)
7. Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis. Brancaccio D, Ghiggeri GM, Braidotti P, Garberi A, Gallieni M, Bellotti V, Zoni U, Gusmano R, Coggi G, J Am Soc Nephrol 1995 6 1262 1270
8. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. de Sousa MM, Vital C, Ostler D, Fernandes R, Pouget-Abadie J, Carles D, Saraiva MJ, Am J Pathol 2000 156 1911 1917 (Pubitemid 30641760)
9. Ultrastructural evidence for colocalization of kappa light chain- and beta 2-microglobulin-derived amyloids using double labelling immunogold electron microscopy. Takahashi M, Hoshii Y, Kawano H, Gondo T, Ishihara T, Isobe T, Virchows Arch 1996 429 383 388 (Pubitemid 26421400)
10. Transthyretin and the Transthyretin Amyloidoses. Buxbaum JN, Protein Misfolding, Aggregation, and Conformational Diseases Santa Cruz, California: Springer, Uversky VN, Fink A, 2007 259 283
11. Cerebrospinal fluid inhibits Alzheimer beta-amyloid fibril formation in vitro. Wisniewski T, Castano E, Ghiso J, Frangione B, Ann Neurol 1993 34 631 633 (Pubitemid 23289420)
12. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, Proc Natl Acad Sci USA 1994 91 8368 8372 (Pubitemid 24273665)
13. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD, Proc Natl Acad Sci USA 1993 90 8098 8102 (Pubitemid 23260862)
14. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T, Frangione B, Biochem J 1993 293 Pt 1 27 30 (Pubitemid 23223142)
15. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Wisniewski T, Frangione B, Neurosci Lett 1992 135 235 238
16. Transthyretin and Alzheimer's disease: where in the brain? Sousa JC, Cardoso I, Marques F, Saraiva MJ, Palha JA, Neurobiol Aging 2007 28 713 718 (Pubitemid 46349354)
17. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Kosik KS, Joachim CL, Selkoe DJ, Proc Natl Acad Sci USA 1986 83 4044 4048 (Pubitemid 16062419)
18. Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Goedert M, Spillantini MG, Cairns NJ, Crowther RA, Neuron 1992 8 159 168
19. Phosphorylated Tau protein is integrated into paired helical filaments in Alzheimer's disease. Ihara Y, Nukina N, Miura R, Ogawara M, J Biochem (Tokyo) 1986 99 1807 1810
20. Alzheimer's disease. Blennow K, de Leon MJ, Zetterberg H, Lancet 2006 368 387 403 (Pubitemid 44108123)
21. Inflammation and Alzheimer's disease. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. Neurobiol Aging 2005 21 383 421 (Pubitemid 30349107)
22. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Wyss-Coray T, Nat Med 2006 12 1005 1015 (Pubitemid 44353380)
23. Oxidative stress and Alzheimer disease1. Christen Y, Am J Clin Nutr 2000 71 621s 629s
24. Oxidative stress hypothesis in Alzheimer's disease. Markesbery WR, Free Radic Biol Med 1997 23 134 147 (Pubitemid 27217017)
25. Oxidative stress and neurotoxicity. Sayre LM, Perry G, Smith MA, Chem Res Toxicol 2007 21 172 188 (Pubitemid 351219718)
26. [beta]-Amyloid of Alzheimer's disease induces reactive gliosis that inhibits axonal outgrowth. Canning DR, McKeon RJ, DeWitt DA, Perry G, Wujek JR, Frederickson RCA, Silver J, Exp Neurol 1993 124 289 298
27. Intracellular amyloid-[beta] in Alzheimer's disease. LaFerla FM, Green KN, Oddo S, Nat Rev Neurosci 2007 8 499 509
28. Mechanisms of disease alzheimer's disease. Querfurth HW, LaFerla FM, N Engl J Med 2010 362 329 344
29. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. Gandy S, J Clin Invest 2005 115 1121 1129 (Pubitemid 40629026)
30. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B, Nature 1987 325 733 736 (Pubitemid 17054046)
31. Twenty years of the alzheimer's disease amyloid hypothesis: A genetic perspective. Tanzi RE, Bertram L, Cell 2005 120 545 555 (Pubitemid 40269768)
32. ADAMs family members as amyloid precursor protein alpha-secretases. Allinson TM, Parkin ET, Turner AJ, Hooper NM, J Neurosci Res 2003 74 342 352 (Pubitemid 37362810)
33. Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Koike H, Tomioka S, Sorimachi H, Saido TC, Maruyama K, Okuyama A, Fujisawa-Sehara A, Ohno S, Suzuki K, Ishiura S, Biochem J 1999 343 Pt 2 371 375 (Pubitemid 29511770)
34. Putative function of ADAM9, ADAM10, and ADAM17 as APP [alpha]-secretase. Asai M, Hattori C, Szabá B, Sasagawa N, Maruyama K, Tanuma Si, Ishiura S, Biochem Biophys Res Commun 2003 301 231 235 (Pubitemid 36268873)
35. Constitutive and regulated -secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F, Proc Natl Acad Sci USA 1999 96 3922 3927 (Pubitemid 29169012)
36. ADAM19 is tightly associated with constitutive Alzheimer's disease APP alpha-secretase in A172 cells. Tanabe C, Hotoda N, Sasagawa N, Sehara-Fujisawa A, Maruyama K, Ishiura S, Biochem Biophys Res Commun 2007 352 111 117 (Pubitemid 44821101)
37. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA, J Biol Chem 1998 273 27765 27767 (Pubitemid 28496060)
38. Peptides containing the RERMS sequence of amyloid beta/A4 protein precursor bind cell surface and promote neurite extension. Jin LW, Ninomiya H, Roch JM, Schubert D, Masliah E, Otero DA, Saitoh T, J Neurosci 1994 14 5461 5470 (Pubitemid 24279065)
39. Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. Mattson MP, J Neurobiol 1994 25 439 450
40. Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, Abraham CR, Brain Res 1994 666 151 167 (Pubitemid 24369026)
41. Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor. Roch JM, Masliah E, Roch-Levecq AC, Sundsmo MP, Otero DA, Veinbergs I, Saitoh T, Proc Natl Acad Sci USA 1994 91 7450 7454 (Pubitemid 24238201)
42. Memory-enhancing effects of secreted forms of the -amyloid precursor protein in normal and amnestic mice. Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A, Proc Natl Acad Sci USA 1998 95 12683 12688 (Pubitemid 28483825)
43. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE, Neuron 1993 10 243 254 (Pubitemid 23079546)
44. Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Goodman Y, Mattson MP, Exp Neurol 1994 128 1 12
45. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Mattson MP, Physiol Rev 1997 77 1081 1132 (Pubitemid 27459580)
46. {Beta}-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. Science 1999 286 735 741
47. Purification and cloning of amyloid precursor protein [beta]-secretase from human brain. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, et al. Nature 1999 402 537 540
48. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC, Nat Neurosci 2001 4 233 234 (Pubitemid 32194867)
49. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, et al. Nat Neurosci 2001 4 231 232 (Pubitemid 32194866)
50. Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradszky KF, Neveu J, Lane W, Hook G, Reisine T, Biol Chem 2005 386 931 940 (Pubitemid 41448149)
51. Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. Hook V, Kindy M, Hook G, Biol Chem 2007 388 247 252 (Pubitemid 46184154)
52. Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway. Hook VY, Reisine TD, J Neurosci Res 2003 74 393 405 (Pubitemid 37362816)
53. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nikolaev A, McLaughlin T, O'Leary DDM, Tessier-Lavigne M, Nature 2009 457 981 989
54. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and [gamma]-secretase activity. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ, Nature 1999 398 513 517
55. Alzheimer's disease. Closing in on gamma-secretase. De Strooper B, Nature 2000 405 627 628
56. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. De Strooper B, Neuron 2003 38 9 12 (Pubitemid 36423348)
57. Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases. Haass C, Steiner H, Trends Cell Biol 2002 12 556 562 (Pubitemid 35461853)
58. Assembly, trafficking and function of gamma-secretase. Kaether C, Haass C, Steiner H, Neurodegener Dis 2006 3 275 283
59. Gamma-secretase: never more enigmatic. Sisodia SS, Annaert W, Kim SH, De Strooper B, Trends Neurosci 2001 24 2 S6
60. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics - Relevance for Alzheimer's disease. Müller T, Meyer HE, Egensperger R, Marcus K, Prog Neurobiol 2008 85 393 406
61. The Role of Presenilins in -Secretase Activity. Wolfe MS, Haass C, J Biol Chem 2001 276 5413 5416
62. Take five - BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. Haass C, EMBO J 2004 23 483 488 (Pubitemid 38282380)
63. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ, Proc Natl Acad Sci USA 1993 90 10836 10840
64. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y, Neuron 1994 13 45 53
65. Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. Turner RS, Suzuki N, Chyung AS, Younkin SG, Lee VM, J Biol Chem 1996 271 8966 8970
66. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, Golde TE, Younkin SG, Science 1994 264 1336 1340
67. Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, Lee VM, Doms RW, Nat Med 1997 3 1021 1023 (Pubitemid 27391958)
68. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, et al. Nat Med 1997 3 1016 1020 (Pubitemid 27391957)
69. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. Koo EH, Squazzo SL, J Biol Chem 1994 269 17386 17389 (Pubitemid 24218009)
70. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. Chung H, Brazil MI, Soe TT, Maxfield FR, J Biol Chem 1999 274 32301 32308
71. Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Nielsen HM, Mulder SD, Belien JA, Musters RJ, Eikelenboom P, Veerhuis R, Glia 2010 58 1235 1246
72. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van NW, et al. Nat Cell Biol 2009 11 143 153
73. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, et al. J Clin Invest 2000 106 1489 1499 (Pubitemid 32038587)
74. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA, J Neurochem 2010 115 1077 1089
75. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Tanzi RE, Moir RD, Wagner SL, Neuron 2004 43 605 608 (Pubitemid 39179722)
76. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione B, et al. J Clin Invest 1998 102 734 743 (Pubitemid 28399606)
77. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Deane R, Du YS, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, et al. Nat Med 2003 9 907 913 (Pubitemid 36889934)
78. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ, J Biol Chem 1998 273 32730 32738 (Pubitemid 28557658)
79. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. Hemming ML, Selkoe DJ, J Biol Chem 2005 280 37644 37650 (Pubitemid 41642372)
80. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. Hu J, Igarashi A, Kamata M, Nakagawa H, J Biol Chem 2001 276 47863 47868
81. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, et al. Neuron 2006 51 703 714 (Pubitemid 44374903)
82. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB, J Biol Chem 2003 278 2081 2084 (Pubitemid 36801269)
83. Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain. Kim MJ, Chae SS, Koh YH, Lee SK, Jo SA, FASEB J 2010 24 4491 4502
84. Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Roher AE, Kasunic TC, Woods AS, Cotter RJ, Ball MJ, Fridman R, Biochem Biophys Res Commun 1994 205 1755 1761
85. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). Backstrom JR, Lim GP, Cullen MJ, Tokes ZA, J Neurosci 1996 16 7910 7919 (Pubitemid 26405054)
86. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, et al. J Biol Chem 2006 281 24566 24574 (Pubitemid 44274231)
87. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, et al. Proc Natl Acad Sci USA 2008 105 8754 8759 (Pubitemid 351987752)
88. The plasmin system is induced by and degrades amyloid-beta aggregates. Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, Walker D, Scheff S, McGillis JP, Rydel RE, et al. J Neurosci 2000 20 3937 3946 (Pubitemid 30365663)
89. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, et al. Nat Med 2000 6 143 150 (Pubitemid 30082357)
90. Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, et al. J Biol Chem 2001 276 21895 21901
91. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. Kurochkin IV, Goto S, FEBS Lett 1994 345 33 37
92. Metabolic regulation of brain Abeta by neprilysin. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC, Science 2001 292 1550 1552 (Pubitemid 32493424)
93. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Farris W, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, et al. Am J Pathol 2007 171 241 251 (Pubitemid 47339241)
94. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S, Proc Natl Acad Sci USA 2003 100 4162 4167 (Pubitemid 36418174)
95. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ, PLoS Med 2007 4 262
96. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ, Neuron 2003 40 1087 1093 (Pubitemid 38032786)
97. ApoE promotes the proteolytic degradation of Abeta. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, et al. Neuron 2008 58 681 693 (Pubitemid 351778466)
98. Toward a comprehensive theory for Alzheimer's disease. hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid protein. Selkoe DJ, Ann N Y Acad Sci 2000 924 17 25 (Pubitemid 32050177)
99. Alzheimer's disease: Genes, proteins, and therapy. Selkoe DJ, Physiol Rev 2001 81 741 766 (Pubitemid 32267077)
100. Alzheimer's disease is a synaptic failure. Selkoe DJ, Science 2002 298 789 791 (Pubitemid 35231524)
101. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 353 356 (Pubitemid 34790756)
102. Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Glenner GG, Wong CW, Biochem Biophys Res Commun 1984 122 1131 1135 (Pubitemid 14027629)
103. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K, Proc Natl Acad Sci USA 1985 82 4245 4249 (Pubitemid 15053619)
104. A possible unitary genetic hypothesis for Alzheimer's disease and Down syndromea. Schweber M, Ann N Y Acad Sci 1985 450 223 238 (Pubitemid 15070376)
105. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. Haass C, Hung AY, Selkoe DJ, Teplow DB, J Biol Chem 1994 269 17741 17748
106. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Rogaev EI, Sherrington R, Rogaeva E, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al. Nature 1995 376 775 778
107. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Sherrington R, Rogaev E, Liang Y, Rogaeva E, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Nature 1995 375 754 760
108. Mutation of the [beta]-amyloid precursor protein in familial Alzheimer's disease increases [beta]-protein production. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ, Nature 1992 360 672 674 (Pubitemid 23007680)
109. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid [beta]-protein in both transfected cells and transgenic mice. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-wood K, Lee M, Seubert P, Davis A, et al. Nat Med 1997 3 67 72 (Pubitemid 27019143)
110. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid protein ending at the 42nd (or 43rd) residue. Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, Capell A, Walter J, Jürgen G, Haass C, et al. Proc Natl Acad Sci USA 1997 94 2025 2030 (Pubitemid 27113955)
111. The Swedish mutation causes early-onset Alzheimer's disease by [beta]-secretase cleavage within the secretory pathway. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ, Nat Med 1995 1 1291 1296
112. A decade of modeling Alzheimer's disease in transgenic mice. McGowan E, Eriksen J, Hutton M, Trends Genet 2006 22 281 289
113. Probing the biology of Alzheimer's disease in mice. Ashe KH, Zahs KR, Neuron 2010 66 631 645
114. Alzheimer disease models and human neuropathology: similarities and differences. Duyckaerts C, Potier MC, Delatour B, Acta Neuropathol 2008 115 5 38 (Pubitemid 50005258)
115. Soluble pool of A amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Vbeyreuther K, Bush AI, Masters CL, Ann Neurol 1999 46 860 866
116. Soluble amyloid {beta} peptide concentration as a predictor of synaptic change in Alzheimer's disease. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J, Am J Pathol 1999 155 853 862 (Pubitemid 29426831)
117. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ, Nature 2002 416 535 539 (Pubitemid 34288854)
118. Natural oligomers of the Alzheimer amyloid-{beta} protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL, J Neurosci 2007 27 2866 2875 (Pubitemid 46438992)
119. Amyloid-[beta] protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. Nat Med 2008 14 837 842
120. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, Podlisny MB, Cleary JP, Ashe KH, Rowan MJ, et al. Biochem Soc Trans 2005 33 1087 1090 (Pubitemid 41659119)
121. Cellular prion protein mediates impairment of synaptic plasticity by amyloid- ligomers. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM, Nature 2009 457 1128 1132
122. The prion protein as a receptor for amyloid- Kessels HW, Nguyen LN, Nabavi S, Malinow R, Nature 2010 466 3 E4
123. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT, Neurology 1992 42 631 639
124. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT, Ann Neurol 1997 41 17 24 (Pubitemid 27057088)
125. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, et al. JAMA 2009 302 385 393
126. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L, Lancet Neurol 2006 5 228 234 (Pubitemid 43238346)
127. Evaluation of CSF-tau and CSF-A{beta}42 as diagnostic markers for Alzheimer disease in clinical practice. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K, Arch Neurol 2001 58 373 379 (Pubitemid 32217453)
128. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Strozyk D, Blennow K, White LR, Launer LJ, Neurology 2003 60 652 656 (Pubitemid 36246085)
129. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, et al. Ann Neurol 2009 65 403 413
130. Diffusible, nonfibrillar ligands derived from A beta(1-42) are potent central nervous system neurotoxins. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, et al. Proc Natl Acad Sci USA 1998 95 6448 6453
131. A beta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL, J Biol Chem 2007 282 11590 11601 (Pubitemid 47100810)
132. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. Wang X, Su B, Lee Hg, Li X, Perry G, Smith MA, Zhu X, J Neurosci 2009 29 9090 9103
133. Oxidative damage in Alzheimer's. Smith MA, Perry G, Richey PL, Sayrec LM, Anderson VE, Beal MF, Kowall N, Nature 1996 382 120 121
134. The role of Apolipoprotein E in Alzheimer's disease. Kim J, Basak JM, Holtzman DM, Neuron 2009 63 287 303
135. An alternative interpretation of the amyloid A hypothesis with regard to the pathogenesis of Alzheimer's disease. Marchesi VT, Proc Natl Acad Sci USA 2005 102 9093 9098 (Pubitemid 40923523)
136. The genetics of axonal transport and axonal transport disorders. Duncan JE, Goldstein LSB, PLoS Genet 2006 2 124
137. The Alzheimer's brain: Finding out what's broken tells us how to fix it. Trojanowski JQ, Lee VMY, Am J Pathol 2005 167 1183 1188 (Pubitemid 41541405)
138. Amyloid- in Alzheimer disease: The null versus the alternate hypotheses. Lee Hg, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA, J Pharmacol Exp Ther 2007 321 823 829 (Pubitemid 46762675)
139. Are Abeta and its derivatives causative agents or innocent bystanders in AD? Robakis NK, Neurodegener Dis 2010 7 32 37
140. Mechanisms of AD neurodegeneration may be independent of Abeta and its derivatives. Robakis NK, Neurobiol Aging 2011 32 372 379
141. Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Robinson SR, Bishop GM, Neurobiol Aging 2002 23 1051 1072 (Pubitemid 35447787)
142. Arson. Tracking the culprit in Alzheimer's disease. Smith MA, Joseph JA, Perry G, Ann N Y Acad Sci 2000 924 35 38 (Pubitemid 32050180)
143. Progress in Alzheimer's disease drug discovery: an update. Williams M, Curr Opinion Invest Drugs 2008 10 23 34
144. Neuropathology after active Abeta42 immunotherapy: implications for
145. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW, Acc Chem Res 2005 38 911 921
146. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, et al. Ann Med 2008 40 232 239 (Pubitemid 351482541)
147. Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old. Lie JT, Hammond PI, Mayo Clinic Proc 1988 63 552 564
148. Tabulation of human transthyretin (TTR) variants, 2003. Connors L, Lim A, Prokaeva T, Roskens VA, Costello CE, Amyloid 2003 10 160 184 (Pubitemid 37372400)
149. Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). Garzuly F, Vidal R, Wisniewski T, Brittig F, Budka H, Neurol 1996 47 1562 1567 (Pubitemid 26422555)
150. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Sekijima Y, Hammarstrom P, Matsumura M, Shimizu Y, Iwata M, Tokuda T, Ikeda S, Kelly JW, Lab Invest 2003 83 409 417 (Pubitemid 36351002)
151. Three-dimensional structure of the transthyretin-retinol-binding protein complex. Monaco HL, Clin Chem Lab Med 2002 40 1229 1236 (Pubitemid 36024660)
152. Binding of thyroid hormones and analogues to the human plasma protein prealbumin. Andrea TA, Cavalieri RR, Goldfine ID, Jorgensen EC, Biochemistry 1980 19 55 63 (Pubitemid 10154185)
153. The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex. Raz A, J Biol Chem 1969 244 3230 3237
154. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid-hormone. Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ, Proc Natl Acad Sci USA 1993 90 2375 2379 (Pubitemid 23078629)
155. Transthyretin is not essential for thyroxine to reach the brain and other tissues in transthyretin-null mice. Palha JA, Hays MT, Morreale de EG, Episkopou V, Gottesman ME, Saraiva MJ, Am J Physiol 1997 272 485 E493
156. Studies on the metabolism of retinol and retinol-binding protein in transthyretin-deficient mice produced by homologous recombination. Wei S, Episkopou V, Piantedosi R, Maeda S, Shimada K, Gottesman ME, Blaner WS, J Biol Chem 1995 270 866 870
157. Transthyretin is involved in depression-like behaviour and exploratory activity. Sousa JC, Grandela C, Fernandez-Ruiz J, de Miguel R, de Sousa L, Magalhaes AI, Saraiva MJ, Sousa N, Palha JA, J Neurochem 2004 88 1052 1058 (Pubitemid 38280673)
158. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of A beta toxicity. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T, Proc Natl Acad Sci USA 2008 105 2681 2686 (Pubitemid 351520573)
159. Transthyretin knockouts are a new mouse model for increased neuropeptide Y. Nunes AF, Saraiva MJ, Sousa MM, FASEB J 2006 20 166 168 (Pubitemid 43100502)
160. Transthyretin enhances nerve regeneration. Fleming CE, Saraiva MJ, Sousa MM, J Neurochem 2007 103 831 839 (Pubitemid 47498041)
161. Cell division and apoptosis in the adult neural stem cell niche are differentially affected in transthyretin null mice. Richardson SJ, Lemkine GF, Alfama G, Hassani Z, Demeneix BA, Neurosci Lett 2007 421 234 238 (Pubitemid 46935362)
162. Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division Committee on Plasma Proteins (C-PP). Myron Johnson A, Clin Chem Lab Med 2007 45 419 426
163. Characterization of serum biomarkers for detection of early stage ovarian cancer. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R, Proteomics 2005 5 4589 4596 (Pubitemid 41739936)
164. Reduced transthyretin expression in sera of lung cancer. Liu L, Liu J, Dai S, Wang X, Wu S, Wang J, Huang L, Xiao X, He D, Cancer Sci 2007 98 1617 1624 (Pubitemid 47308460)
165. Transthyretin: A choroid plexus-specific transport protein in human brain: The 1986 S. Weir Mitchell Award. Herbert J, Wilcox JN, Pham KT, Fremeau RT Jr, Zeviani M, Dwork A, Soprano DR, Makover A, Goodman DS, Zimmerman EA, et al. Neurology 1986 36 900
166. Transthyretin localization in cultured and native human retinal pigment epithelium. Getz RK, Kennedy BG, Mangini NJ, Exp Eye Res 1999 68 629 636 (Pubitemid 29244150)
167. Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation. Schwarzman AL, Goldgaber D, Ciba Found Symp 1996 199 146 160
168. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APP(Sw) mice resulting in tau phosphorylation and loss of hippocampal neurons: Support for the amyloid hypothesis. Stein TD, Anders NJ, Decarli C, Chan SL, Mattson MP, Johnson JA, J Neurosci 2004 24 7707 7717 (Pubitemid 39186826)
169. Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective? Li X, Masliah E, Reixach N, Buxbaum JN, J Neurosci 2011 31 12483 12490
170. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Carro E, Trejo JL, Gerber A, Loetscher H, Torrado J, Metzger F, Torres-Aleman I, Neurobiol Aging 2006 27 1250 1257 (Pubitemid 44088577)
171. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. Stein TD, Johnson JA, J Neurosci 2002 22 7380 7388 (Pubitemid 35386337)
172. DNA variation and brain region-specific expression profiles exhibit different relationships between inbred mouse strains: implications for eQTL mapping studies. Hovatta I, Schadt EE, Libiger O, Schork NJ, Lockhart DJ, Barlow C, Zapala MA, Broide RS, Genome Biol 2007 8 25
173. Rat choroid plexus specializes in the synthesis and the secretion of transthyretin (prealbumin). Regulation of transthyretin synthesis in choroid plexus is independent from that in liver. Dickson PW, Aldred AR, Marley PD, Bannister D, Schreiber G, J Biol Chem 1986 261 3475 3478 (Pubitemid 17200640)
174. The transthyretin gene is expressed in human and rodent dorsal root ganglia. Murakami T, Ohsawa Y, Sunada Y, Neurosci Lett 2008 436 335 339
175. Transthyretin is not expressed by dorsal root ganglia cells. Sousa MM, Saraiva MJ, Exp Neurol 2008 214 362 365
176. The transthyretin gene is expressed in Schwann cells of peripheral nerves. Murakami T, Ohsawa Y, Zhenghua L, Yamamura Ki, Sunada Y, Brain Res 2010 1348 222 225
177. An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer's dementia. Eikelenboom P, Stam FC, Virchows Arch B Cell Pathol Incl Mol Pathol 1984 47 17 25 (Pubitemid 14017292)
178. Senile cerebral amyloid. Prealbumin as a common constituent in the neuritic plaque, in the neurofibrillary tangle, and in the microangiopathic lesion. Shirahama T, Skinner M, Westermark P, Rubinow A, Cohen AS, Brun A, Kemper TL, Am J Pathol 1982 107 41 50 (Pubitemid 12153224)
179. An anatomic gene expression atlas of the adult mouse brain. Ng L, Bernard A, Lau C, Overly CC, Dong HW, Kuan C, Pathak S, Sunkin SM, Dang C, Bohland JW, et al. Nat Neurosci 2009 12 356 362
180. Cerebrospinal fluid transthyretin: Aging and late onset Alzheimer's disease. Serot JM, Christmann D, Dubost T, Couturier M, J Neurol Neurosurg Psychiatry 1997 63 506 508 (Pubitemid 27423560)
181. Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease. Riisoen H, Acta Neurol Scand 1988 78 455 459 (Pubitemid 19017783)
182. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K, J Alzheimers Dis 2009 16 389 397
183. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, Zerr I, J Alzheimers Dis 2008 14 17 25 (Pubitemid 352039015)
184. Comparative proteomics of cerebrospinal fluid in neuropathologically- confirmed Alzheimer's disease and non-demented elderly subjects. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T, Neurol Res 2006 28 155 163
185. Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. Schultz K, Nilsson K, Nielsen JE, Lindquist SG, Hjermind LE, Andersen BB, Wallin A, Nilsson C, Petersen A, Eur J Neurol 2010 17 456 460
186. Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families. Cuenco KT, Friedland R, Baldwin CT, Guo J, Vardarajan B, Lunetta KL, Cupples LA, Green RC, Decarli C, Farrer LA, Neurobiol Aging 2011 32 249 256
187. Transthyretin gene in Alzheimer's disease patients. Palha JA, Moreira P, Wisniewski T, Frangione B, Saraiva MJ, Neurosci Lett 1996 204 212 214 (Pubitemid 26054677)
188. CSF transthyretin in patients with depression. Hatterer JA, Herbert J, Hidaka C, Roose SP, Gorman JM, Am J Psychiatry 1993 150 813 815 (Pubitemid 23137692)
189. Transthyretin in cerebrospinal fluid from suicide attempters. Schultz K, Traskman-Bendz L, Petersen A, J Affect Disord 2008 109 205 208
190. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Brettschneider J, Lehmensiek V, Mogel H, Pfeifle M, Dorst J, Hendrich C, Ludolph AC, Tumani H, Neurosci Lett 2010 468 23 27
191. Transthyretin binds amyloid [beta] peptides, A[beta]1-42 and A[beta]1-40 to form complex in the autopsied human kidney-possible role of transthyretin for A[beta] sequestration. Tsuzuki K, Fukatsu R, Yamaguchi H, Tateno M, Imai K, Fujii N, Yamauchi T, Neurosci Lett 2000 281 171 174 (Pubitemid 30125892)
192. Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele. Askanas V, Engel WK, Alvarez RB, Frangione B, Ghiso J, Vidal R, Annals of Neurol 2000 47 544 549 (Pubitemid 30194617)
193. A sensitive assay of transthyretin (prealbumin) in human cerebrospinal fluid in nanogram amounts by ELISA. Vatassery GT, Quach HT, Smith WE, Benson BA, Eckfeldt JH, Clin Chim Acta 1991 197 19 25
194. Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Price JM, Chi X, Hellermann G, Sutton ET, Neurol Res 2001 23 506 512 (Pubitemid 32642784)
195. Improved discrimination of AD patients using {beta}-amyloid(1-42) and tau levels in CSF. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, Deyn PPD, Bancher C, Cras P, Wiltfang J, Mehta PD, et al. Neurology 1999 52 1555
196. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Link CD, Proc Natl Acad Sci USA 1995 92 9368 9372
197. Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Wu ZL, Ciallella JR, Flood DG, O'kane TM, Bozyczko-Coyne D, Savage MJ, Neurobiol Aging 2006 27 377 386 (Pubitemid 43185323)
198. Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). Choi SH, Leight SN, Lee VM, Li T, Wong PC, Johnson JA, Saraiva MJ, Sisodia SS, J Neurosci 2007 27 7006 7010 (Pubitemid 47015887)
199. Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease. Wati H, Kawarabayashi T, Matsubara E, Kasai A, Hirasawa T, Kubota T, Harigaya Y, Shoji M, Maeda S, Brain Pathol 2009 19 48 57
200. Possible involvement of transthyretin in hippocampal beta-amyloid burden and learning behaviors in a mouse model of Alzheimer's disease (TgCRND8). Doggui S, Brouillette J, Chabot JG, Farso M, Quirion R, Neurodegener Dis 2010 7 88 95
201. Preparation of amyloid beta-protein for structural and functional studies. Teplow DB, Methods Enzymol 2006 413 20 33 (Pubitemid 44528683)
202. Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Schwarzman AL, Tsiper M, Wente H, Wang A, Vitek MP, Vasiliev V, Goldgaber D, Amyloid 2004 11 1 9 (Pubitemid 38680232)
203. Transthyretin binding to A-Beta peptide-Impact on A-Beta fibrillogenesis and toxicity. Costa R, Goncalves A, Saralva MJ, Cardoso I, FEBS Lett 2008 582 936 942
204. Transthyretin inhibition of amyloid beta aggregation and toxicity. Giunta S, Valli MB, Galeazzi R, Fattoretti P, Corder EH, Galeazzi L, Clin Biochem 2005 38 1112 1119 (Pubitemid 41797752)
205. Kinetics of inhibition of beta-amyloid aggregation by transthyretin. Liu L, Murphy RM, Biochemistry (Mosc) 2006 45 15702 15709 (Pubitemid 46032490)
206. Characterization of the interaction of beta-amyloid with transthyretin monomers and tetramers. Du J, Murphy RM, Biochemistry (Mosc) 2010 49 8276 8289
207. Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's [beta]-amyloid peptide in cultured vascular smooth muscle cells. Mazur-Kolecka Bcdae, Frackowiak J, Wisniewski HM, Brain Res 1995 698 217 222
208. Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I, Plos ONE 2008 3 2899
209. The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. Matsuda S, Giliberto L, Matsuda Y, Davies P, McGowan E, Pickford F, Ghiso J, Frangione B, D'Adamio L, J Biol Chem 2005 280 28912 28916 (Pubitemid 41161336)
210. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, et al. J Neurosci 2003 23 29 33 (Pubitemid 36050401)
211. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. Deane R, Bell RD, Sagare A, Zlokovic BV, CNS Neurol Disord Drug Targets 2009 8 16 30
212. Adapting proteostasis for disease intervention. Balch WE, Morimoto RI, Dillin A, Kelly JW, Science 2008 319 916 919 (Pubitemid 351263754)
213. Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, Sommer J, Schmidt SD, Nixon RA, Mathews PM, et al. Nat Genet 2007 39 1440 1442 (Pubitemid 350191347)
214. Cystatin C modulates cerebral beta-amyloidosis. Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT, Staufenbiel M, Levy E, Grubb A, Jucker M, Nat Genet 2007 39 1437 1439
215. BRI2 (ITM2b) Inhibits Abeta Deposition in Vivo. Kim J, Miller VM, Levites Y, Jansen-West K, Zwizinski CW, Moore BD, Troendle FJ, Bann M, Verbeeck C, Price RW, et al. J Neurosci 2008 28 6030 6036
216. A stop-codon mutation in the BRI gene associated with familial British dementia. Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, Ghiso J, Nature 1999 399 776 781 (Pubitemid 29293172)
217. Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Ray I, Chauhan A, Wegiel J, Chauhan VPS, Brain Res 2000 853 344 351 (Pubitemid 30035235)
218. Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease. Chauhan V, Ji L, Chauhan A, Biogerontology 2008 9 381 389
219. Neuroprotective Effects of Natural Products: Interaction with Intracellular Kinases, Amyloid Peptides and a Possible Role for Transthyretin. Bastianetto S, Brouillette J, Quirion R, Neurochem Res 2007 32 1720 1725 (Pubitemid 47428851)
220. Transthyretin: a key gene involved in the maintenance of memory capacities during aging. Brouillette J, Quirion R, Neurobiol Aging 2008 29 1721 1732
221. ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. Liz MA, Gomes CM, Saraiva MJ, Sousa MM, J Lipid Res 2007 48 2385 2395 (Pubitemid 350058750)
222. Transthyretin: the servant of many masters. Buxbaum JN, Reixach N, Cell Mol Life Sci 2009 66 3095 3101
223. Genetic programming by the proteolytic fragments of the amyloid precursor protein: somewhere between confusion and clarity. Stein TD, Johnson JA, Rev Neurosci 2003 14 317 341 (Pubitemid 37462289)
224. Dissection of Amyloid- precursor protein-dependent transcriptional transactivation. Cao X, Südhof TC, J Biol Chem 2004 279 24601 24611 (Pubitemid 38725327)
225. Presenilin-Dependent Transcriptional Control of the A[beta]-Degrading Enzyme Neprilysin by Intracellular Domains of [beta]APP and APLP. Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, Ring S, D'Adamio L, Shen J, Mnller U, et al. Neuron 2005 46 541 554 (Pubitemid 40797380)
226. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. von Rotz RC, Kohli BM, Bosset J, Meier M, Suzuki T, Nitsch RM, Konietzko U, J Cell Sci 2004 117 4435 4448 (Pubitemid 39360070)
227. A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Cao X, Südhof TC, Science 2001 293 115 120 (Pubitemid 32625507)
228. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G, Neuron 2007 56 66 78 (Pubitemid 47484175)
229. Presenilin/-secretase-dependent processing of -amyloid precursor protein regulates EGF receptor expression. Zhang Yw, Wang R, Liu Q, Zhang H, Liao FF, Xu H, Proc Natl Acad Sci USA 2007 104 10613 10618 (Pubitemid 47185713)
230. Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE, Südhof TC, Zheng H, Proc Natl Acad Sci USA 2010 107 17362 17367
231. Environmental enrichment reduces a[beta] levels and amyloid deposition in transgenic mice. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VMY, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS, Cell 2005 120 701 713 (Pubitemid 40343081)
232. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Watanabe CM, Wolffram S, Ader P, Rimbach G, Packer L, Maguire JJ, Schultz PG, Gohil K, Proc Natl Acad Sci USA 2001 98 6577 6580 (Pubitemid 32538258)
233. Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Puskás LG, Kitajka K, Nyakas C, Barcelo-Coblijn G, Farkas T, Proc Natl Acad Sci USA 2003 100 1580 1585 (Pubitemid 36254490)
234. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Kitajka K, Sinclair AJ, Weisinger RS, Weisinger HS, Mathai M, Jayasooriya AP, Halver JE, Puskas LG, Proc Natl Acad Sci USA 2004 101 10931 10936 (Pubitemid 38989562)
235. Effect of a short- and long-term treatment with Ginkgo biloba extract on amyloid precursor protein levels in a transgenic mouse model relevant to Alzheimer's disease. Augustin S, Rimbach G, Augustin K, Schliebs R, Wolffram S, Cermak R, Arch Biochem Biophys 2009 481 177 182
236. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF, Exp Neurol 2003 184 510 520 (Pubitemid 37444058)
237. Ginkgo biloba for prevention of dementia: a randomized controlled trial. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, et al. JAMA 2008 300 2253 2262
238. Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Hirko AC, Meyer EM, King MA, Hughes JA, Mol Ther 2007 15 1623 1629 (Pubitemid 47289005)
239. Neuroserpin binds Abeta and is a neuroprotective component of amyloid plaques in Alzheimer disease. Kinghorn KJ, Crowther DC, Sharp LK, Nerelius C, Davis RL, Chang HT, Green C, Gubb DC, Johansson J, Lomas DA, J Biol Chem 2006 281 29268 29277 (Pubitemid 44507070)